Ebola antibody cocktail made available in emergency outbreak
NCT ID NCT03576690
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This program provides emergency access to REGN-EB3, a combination of three antibodies, for people with confirmed Ebola virus disease. It is available to both adults and children in Ebola-affected regions, including pregnant women. The goal is to offer a potential treatment option during outbreaks when no other approved therapies are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- REGN-EB3 (a combination of three antibodies: atoltivimab, maftivimab, and odesivimab)
- What this could lead to
- If effective, this treatment could help control Ebola virus disease and improve survival rates during outbreaks.
- What could go wrong
- This is an expanded access program, not a controlled trial, so results may be less reliable. The treatment may not work for all patients and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ebola vaccine trial aims to shield frontline workers in congo
- Ebola vaccine in a nasal spray? early trial halted
- Ebola vaccine memory under the microscope: how long does it last?
- Could a vaccine and antibody combo stop ebola after exposure?
- UK volunteers test new ebola vaccine combo in Early-Stage trial
- Hope in a pill? ebola drug favipiravir tested in guinea